Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Intention to Treat Analysis | 4 | 2018 | 673 | 2.01 | Why? |
| Causality | 5 | 2020 | 857 | 1.86 | Why? |
| Mendelian Randomization Analysis | 3 | 2018 | 317 | 1.76 | Why? |
| Pragmatic Clinical Trials as Topic | 2 | 2018 | 350 | 1.23 | Why? |
| Epidemiologic Research Design | 2 | 2017 | 166 | 1.16 | Why? |
| Data Interpretation, Statistical | 5 | 2018 | 657 | 0.98 | Why? |
| Sociometric Techniques | 1 | 2020 | 3 | 0.86 | Why? |
| Sociological Factors | 1 | 2020 | 106 | 0.81 | Why? |
| Randomized Controlled Trials as Topic | 7 | 2019 | 10649 | 0.75 | Why? |
| Bias | 3 | 2018 | 1109 | 0.71 | Why? |
| Epoetin Alfa | 1 | 2017 | 13 | 0.71 | Why? |
| Observation | 1 | 2017 | 80 | 0.69 | Why? |
| AIDS Dementia Complex | 1 | 2018 | 48 | 0.68 | Why? |
| Leukoencephalopathy, Progressive Multifocal | 1 | 2018 | 55 | 0.68 | Why? |
| Toxoplasmosis | 1 | 2018 | 59 | 0.68 | Why? |
| Hematocrit | 1 | 2017 | 107 | 0.68 | Why? |
| Meningitis, Cryptococcal | 1 | 2018 | 79 | 0.66 | Why? |
| Social Perception | 1 | 2021 | 371 | 0.66 | Why? |
| Selection Bias | 1 | 2017 | 201 | 0.64 | Why? |
| Epidemiologic Methods | 1 | 2020 | 392 | 0.62 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 1510 | 0.61 | Why? |
| Epidemiology | 1 | 2018 | 216 | 0.58 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2018 | 260 | 0.57 | Why? |
| Healthy Lifestyle | 1 | 2020 | 447 | 0.57 | Why? |
| Placebos | 1 | 2018 | 629 | 0.57 | Why? |
| Weight Gain | 1 | 2020 | 552 | 0.56 | Why? |
| Research Support as Topic | 1 | 2018 | 327 | 0.52 | Why? |
| Research Design | 4 | 2019 | 5830 | 0.51 | Why? |
| Models, Statistical | 5 | 2021 | 5312 | 0.50 | Why? |
| Evidence-Based Practice | 1 | 2019 | 693 | 0.50 | Why? |
| Coronary Disease | 1 | 2018 | 645 | 0.46 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.45 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 533 | 0.44 | Why? |
| Smoking Cessation | 1 | 2020 | 826 | 0.44 | Why? |
| Population Health | 1 | 2017 | 504 | 0.43 | Why? |
| Survival Analysis | 4 | 2021 | 7592 | 0.43 | Why? |
| Public Opinion | 1 | 2021 | 1165 | 0.43 | Why? |
| Colonoscopy | 1 | 2017 | 738 | 0.42 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.41 | Why? |
| HIV Infections | 6 | 2021 | 11620 | 0.40 | Why? |
| Anemia | 1 | 2017 | 789 | 0.40 | Why? |
| Models, Theoretical | 2 | 2017 | 6659 | 0.36 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.36 | Why? |
| Electronic Health Records | 3 | 2021 | 3492 | 0.35 | Why? |
| Colorectal Neoplasms | 2 | 2018 | 1884 | 0.32 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.31 | Why? |
| Long-Term Care | 1 | 2018 | 2047 | 0.30 | Why? |
| Antihypertensive Agents | 1 | 2018 | 1962 | 0.30 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2021 | 952 | 0.28 | Why? |
| Patient Compliance | 3 | 2021 | 1468 | 0.28 | Why? |
| Periodicals as Topic | 1 | 2018 | 1492 | 0.28 | Why? |
| Health Services Needs and Demand | 1 | 2019 | 3419 | 0.27 | Why? |
| Organ Transplantation | 1 | 2019 | 2616 | 0.26 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.26 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.25 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.25 | Why? |
| Genome-Wide Association Study | 1 | 2010 | 1648 | 0.24 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.24 | Why? |
| Hepatitis B Vaccines | 1 | 2004 | 245 | 0.24 | Why? |
| Drug Overdose | 2 | 2019 | 583 | 0.23 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.23 | Why? |
| Cause of Death | 4 | 2018 | 4823 | 0.21 | Why? |
| Humans | 51 | 2021 | 930598 | 0.21 | Why? |
| Incidence | 7 | 2021 | 25622 | 0.21 | Why? |
| Spain | 8 | 2021 | 15545 | 0.20 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.20 | Why? |
| Researcher-Subject Relations | 1 | 2018 | 4 | 0.19 | Why? |
| Sigmoidoscopy | 1 | 2018 | 50 | 0.18 | Why? |
| Risk Assessment | 4 | 2019 | 25439 | 0.18 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.18 | Why? |
| Preexisting Condition Coverage | 1 | 2018 | 117 | 0.18 | Why? |
| Insurance Claim Review | 1 | 2018 | 108 | 0.18 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.17 | Why? |
| SEER Program | 1 | 2018 | 146 | 0.17 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.17 | Why? |
| Publication Bias | 1 | 2018 | 241 | 0.16 | Why? |
| Americas | 1 | 2018 | 418 | 0.16 | Why? |
| United States | 10 | 2021 | 46150 | 0.16 | Why? |
| Middle Aged | 27 | 2021 | 270681 | 0.16 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.15 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.15 | Why? |
| Atazanavir Sulfate | 1 | 2018 | 213 | 0.15 | Why? |
| Multiple Sclerosis | 2 | 2018 | 2600 | 0.15 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.15 | Why? |
| Genetic Predisposition to Disease | 1 | 2010 | 4027 | 0.14 | Why? |
| Female | 30 | 2021 | 380317 | 0.14 | Why? |
| Monte Carlo Method | 1 | 2017 | 577 | 0.14 | Why? |
| Male | 28 | 2021 | 367725 | 0.14 | Why? |
| Darunavir | 1 | 2018 | 477 | 0.14 | Why? |
| HIV Protease Inhibitors | 1 | 2018 | 434 | 0.13 | Why? |
| Age Distribution | 2 | 2021 | 3567 | 0.13 | Why? |
| Adult | 24 | 2021 | 244371 | 0.13 | Why? |
| Systems Analysis | 1 | 2017 | 366 | 0.13 | Why? |
| Patient Positioning | 2 | 2021 | 1505 | 0.13 | Why? |
| Genetic Variation | 2 | 2018 | 3919 | 0.13 | Why? |
| Disclosure | 1 | 2018 | 423 | 0.13 | Why? |
| Hospital Bed Capacity | 1 | 2021 | 1300 | 0.12 | Why? |
| Prone Position | 2 | 2021 | 1861 | 0.12 | Why? |
| Publications | 1 | 2018 | 463 | 0.12 | Why? |
| Editorial Policies | 1 | 2018 | 408 | 0.12 | Why? |
| Tissue Donors | 2 | 2019 | 1679 | 0.12 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 1454 | 0.12 | Why? |
| Donor Selection | 1 | 2019 | 804 | 0.12 | Why? |
| Risk | 4 | 2021 | 5288 | 0.12 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Patient Preference | 1 | 2018 | 750 | 0.11 | Why? |
| Cohort Studies | 6 | 2021 | 36005 | 0.11 | Why? |
| Aspirin | 2 | 2018 | 1043 | 0.11 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.10 | Why? |
| Psychotic Disorders | 1 | 2021 | 924 | 0.10 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.10 | Why? |
| Aged | 18 | 2021 | 215776 | 0.10 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.10 | Why? |
| Medicare | 1 | 2017 | 1048 | 0.10 | Why? |
| Respiratory Insufficiency | 2 | 2021 | 7301 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.09 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.09 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.09 | Why? |
| Self Report | 1 | 2021 | 3802 | 0.09 | Why? |
| Folic Acid | 1 | 2010 | 172 | 0.09 | Why? |
| Graft Rejection | 1 | 2019 | 1766 | 0.09 | Why? |
| Young Adult | 12 | 2021 | 93724 | 0.09 | Why? |
| Prospective Studies | 6 | 2018 | 43301 | 0.09 | Why? |
| Public Policy | 1 | 2021 | 1894 | 0.09 | Why? |
| Pregnancy Complications | 2 | 2018 | 1388 | 0.09 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.09 | Why? |
| Models, Genetic | 1 | 2010 | 434 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Attitude to Health | 1 | 2021 | 2002 | 0.09 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.08 | Why? |
| Mass Screening | 2 | 2018 | 8005 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.08 | Why? |
| Health Promotion | 2 | 2017 | 2020 | 0.08 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.08 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.08 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.08 | Why? |
| Epilepsy | 1 | 2018 | 1401 | 0.07 | Why? |
| Myocarditis | 1 | 2021 | 2731 | 0.07 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Mobile Applications | 1 | 2021 | 3032 | 0.07 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.07 | Why? |
| Home Childbirth | 1 | 2005 | 65 | 0.07 | Why? |
| Warfare | 1 | 2005 | 90 | 0.07 | Why? |
| Europe | 2 | 2018 | 12702 | 0.07 | Why? |
| Intensive Care Units | 5 | 2021 | 29594 | 0.07 | Why? |
| Environment | 1 | 2010 | 769 | 0.07 | Why? |
| Tetanus Toxoid | 1 | 2004 | 136 | 0.06 | Why? |
| Liver Transplantation | 1 | 2019 | 2864 | 0.06 | Why? |
| Lopinavir | 1 | 2018 | 4308 | 0.06 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.06 | Why? |
| Polymorphism, Genetic | 1 | 2010 | 1074 | 0.06 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.06 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.06 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.06 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.06 | Why? |
| United Kingdom | 2 | 2018 | 18046 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2018 | 1517 | 0.06 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.06 | Why? |
| Israel | 2 | 2021 | 2751 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 5002 | 0.06 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.06 | Why? |
| Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.06 | Why? |
| Registries | 2 | 2018 | 12327 | 0.05 | Why? |
| Kidney Failure, Chronic | 1 | 2017 | 3222 | 0.05 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.05 | Why? |
| Dideoxynucleosides | 1 | 2020 | 92 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Renal Dialysis | 1 | 2017 | 4358 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.05 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.05 | Why? |
| Emtricitabine | 1 | 2020 | 202 | 0.05 | Why? |
| Exercise | 1 | 2020 | 6771 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.05 | Why? |
| Lamivudine | 1 | 2020 | 210 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2019 | 5397 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Pregnancy Outcome | 2 | 2018 | 3803 | 0.05 | Why? |
| Adenine | 1 | 2020 | 463 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.04 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2021 | 6543 | 0.04 | Why? |
| Tenofovir | 1 | 2020 | 449 | 0.04 | Why? |
| Smoking | 1 | 2010 | 3358 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.04 | Why? |
| Herpes Zoster | 1 | 2021 | 331 | 0.04 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.04 | Why? |
| Occult Blood | 1 | 2018 | 275 | 0.04 | Why? |
| Lymphadenopathy | 1 | 2021 | 444 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2018 | 360 | 0.04 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.04 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.04 | Why? |
| Infant | 4 | 2021 | 30274 | 0.04 | Why? |
| Privacy | 1 | 2021 | 636 | 0.04 | Why? |
| Organ Dysfunction Scores | 1 | 2021 | 1475 | 0.03 | Why? |
| Norway | 1 | 2018 | 1004 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.03 | Why? |
| Developed Countries | 1 | 2017 | 500 | 0.03 | Why? |
| Lung Neoplasms | 1 | 2010 | 3228 | 0.03 | Why? |
| Algorithms | 1 | 2010 | 7346 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.03 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Vaccines, Synthetic | 1 | 2004 | 3231 | 0.03 | Why? |
| Appendicitis | 1 | 2021 | 946 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Asthma | 1 | 2010 | 4383 | 0.03 | Why? |
| Veterans | 1 | 2021 | 1131 | 0.03 | Why? |
| Parkinson Disease | 1 | 2003 | 1414 | 0.03 | Why? |
| HIV | 1 | 2018 | 1116 | 0.03 | Why? |
| Risk Reduction Behavior | 1 | 2018 | 946 | 0.03 | Why? |
| Waiting Lists | 1 | 2019 | 1388 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Smartphone | 1 | 2021 | 1840 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Analgesics, Opioid | 1 | 2019 | 1070 | 0.02 | Why? |
| Hemorrhage | 1 | 2021 | 3013 | 0.02 | Why? |
| Influenza Vaccines | 1 | 2004 | 2941 | 0.02 | Why? |
| Cesarean Section | 1 | 2018 | 2089 | 0.02 | Why? |
| Child | 3 | 2021 | 70012 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Public Health | 1 | 2013 | 16359 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Case-Control Studies | 1 | 2004 | 17671 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2021 | 5883 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Primary Health Care | 1 | 2021 | 4839 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Infant Mortality | 1 | 2005 | 268 | 0.02 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.01 | Why? |
| Analgesics, Non-Narcotic | 1 | 2003 | 164 | 0.01 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2005 | 10697 | 0.01 | Why? |
| Maternal Mortality | 1 | 2005 | 461 | 0.01 | Why? |
| Confidence Intervals | 1 | 2003 | 744 | 0.01 | Why? |
| Acetaminophen | 1 | 2003 | 326 | 0.01 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Vaccination | 1 | 2004 | 19050 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Antibodies, Viral | 2 | 2020 | 51949 | 0.01 | Why? |
| Mexico | 1 | 2005 | 2787 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Prenatal Care | 1 | 2005 | 1314 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2003 | 5440 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Retrospective Studies | 1 | 2019 | 105322 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2005 | 8495 | 0.01 | Why? |